Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Abstract Background Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature. Case presentation We present a case of a 29-year-old w...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Gustavo S. Fernandes, Daniel M. Girardi, João Paulo G. Bernardes, Felipe P. Fonseca, Eduardo R. Fregnani
Format:	Article
Language:	English
Published:	BMC 2018-09-01
Subjects:	Ameloblastoma BRAF MAPK Targeted therapy
Online Access:	http://link.springer.com/article/10.1186/s12885-018-4802-y